<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39448488</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1613-3560</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>MMW Fortschritte der Medizin</Title><ISOAbbreviation>MMW Fortschr Med</ISOAbbreviation></Journal><ArticleTitle>[Oxygen therapy in acute and chronic respiratory failure].</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>42</EndPage><MedlinePgn>38-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15006-024-4336-y</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gillissen</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinik für Pneumologie und Beatmungsmedizin, Klinikum Stuttgart - Katharinenhospital, Kriegsbergstr. 60, 70174, Stuttgart, Deutschland. a.gillissen@klinikum-stuttgart.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Sauerstofftherapie beim hypoxischen respiratorischen Versagen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>MMW Fortschr Med</MedlineTA><NlmUniqueID>100893959</NlmUniqueID><ISSNLinking>1438-3276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="Y">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Oxygen therapy is used to reverse hypoxemia in acute and chronic diseases since more than a century. In acute hypoxemic respiratory failure supplementary oxygen remains the first-line therapy in the management of these patients. For chronic hypoxemic patients with an arterial partial pressure of oxygen (PaO2) ≤ 55 mmHg long-term oxygen therapy (LTOT) is recommend when the following conditions are met: increase of PaO2 (or SpO2) with a defined oxygen flow, application time of at least 15 h/day. In patients prone to hyperkapnia oxygen therapy should start at SpO2 &lt; 88% and may not exceed 92%. Hypoxemic patients with normal PaCO2 should receive supplementary oxygen starting at SpO2 &lt;92% and treatment should be stopped at 96%. High-flow oxygen is indicated in patients with severe hypoxemia as in carbon monoxide intoxication, large pneumothorax, exacerbation of interstitial lung diseases or a severe COVID-19 pneumonia. High-flow nasal cannula is a noninvasive form of respiratory support in acute settings with severe hypoxemic respiratory failure. It is seen as a bridge between high-oxygen and non-invasive ventilation, which ancillary effect of a moderate carbon dioxide washout and a PEEP. Clinical efficacy of LTOT should be monitored every 4-12 months. Due to burning risk during oxygen delivery in active smokers prescription of LTOT should be only be made with caution on a case-by-case basis.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39448488</ArticleId><ArticleId IdType="doi">10.1007/s15006-024-4336-y</ArticleId><ArticleId IdType="pii">10.1007/s15006-024-4336-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle>